Ya-gin Chang

TPQ 11529, Taiwan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 10 publications

Protocol for metabolite extraction and sample preparation from primary astrocytes for mass spectrometry-based metabolomic analysis.

Protocol for metabolite extraction and sample preparation from primary astrocytes for mass spectrometry-based metabolomic analysis.

Journal: STAR protocols

Published: December 11, 2025

Corrigendum to "Equilibrative nucleoside transporter 3 supports microglial functions and protects against the progression of Huntington's disease in the mouse model" [Brain Behav. Immun. 120 (2024) 413-429].

Corrigendum to "Equilibrative nucleoside transporter 3 supports microglial functions and protects against the progression of Huntington's disease in the mouse model" [Brain Behav. Immun. 120 (2024) 413-429].

Journal: Brain, behavior, and immunity

Published: August 18, 2024

Equilibrative nucleoside transporter 3 supports microglial functions and protects against the progression of Huntington's disease in the mouse model.

Equilibrative nucleoside transporter 3 supports microglial functions and protects against the progression of Huntington's disease in the mouse model.

Journal: Brain, behavior, and immunity

Published: January 26, 2024

Equilibrative nucleoside transporter 2 modulates inosine catabolism to influence astrocyte metabolism and reactivity.

Equilibrative nucleoside transporter 2 modulates inosine catabolism to influence astrocyte metabolism and reactivity.

Journal: Cell reports

Published: December 07, 2023

Deletion of equilibrative nucleoside transporter 2 disturbs energy metabolism and exacerbates disease progression in an experimental model of Huntington's disease.

Deletion of equilibrative nucleoside transporter 2 disturbs energy metabolism and exacerbates disease progression in an experimental model of Huntington's disease.

Journal: Neurobiology of disease

Published: November 09, 2022

Equilibrative nucleoside transporter 1 inhibition rescues energy dysfunction and pathology in a model of tauopathy.

Equilibrative nucleoside transporter 1 inhibition rescues energy dysfunction and pathology in a model of tauopathy.

Journal: Acta neuropathologica communications

Published: April 21, 2021

Enhanced Na+ -K+ -2Cl- cotransporter 1 underlies motor dysfunction in huntington's disease.

Enhanced Na+ -K+ -2Cl- cotransporter 1 underlies motor dysfunction in huntington's disease.

Journal: Movement disorders : official journal of the Movement Disorder Society

Published: December 10, 2018

Insights into GABAAergic system alteration in Huntington's disease.

Insights into GABAAergic system alteration in Huntington's disease.

Journal: Open biology

Published: September 12, 2018

Exogenous C₈-Ceramide Induces Apoptosis by Overproduction of ROS and the Switch of Superoxide Dismutases SOD1 to SOD2 in Human Lung Cancer Cells.

Exogenous C₈-Ceramide Induces Apoptosis by Overproduction of ROS and the Switch of Superoxide Dismutases SOD1 to SOD2 in Human Lung Cancer Cells.

Journal: International journal of molecular sciences

Published: July 18, 2018

Altered behavioral responses to gamma-aminobutyric acid pharmacological agents in a mouse model of Huntington's disease.

Altered behavioral responses to gamma-aminobutyric acid pharmacological agents in a mouse model of Huntington's disease.

Journal: Movement disorders : official journal of the Movement Disorder Society

Published: December 14, 2016

Showing 1-10 of 10

Last Updated: 09/26/2026